Please login to the form below

Not currently logged in
Email:
Password:

patent cliff

This page shows the latest patent cliff news and features for those working in and with pharma, biotech and healthcare.

Pfizer builds gap between pharma and consumer health units

Pfizer builds gap between pharma and consumer health units

Pfizer CEO described the move as a “natural evolution”for the group as it looks to life beyond 2020 – after which it will have dealt with most of its ‘patent cliff’–

Latest news

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    off the patent cliff in recent years and seen steep sales decline as a result, although a long-acting depot formulation (Abilify Maintena) is still making gains. ... Rexulti is one of a string of new drugs at Lundbeck - along with Abilify and

  • Life lessons Life lessons

    In the case of generics, we’re seeing four variations emerge. Fast followers, like the biosimilar companies, compete by living very close to the edge of the patent cliff.

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    With several new product launches due in 2017, AstraZeneca is hoping to draw a line under a tricky few years punctuated by the loss of patent protection for blockbuster brands. ... The last AZ drug to fall over the 'patent cliff' - cholesterol-lowerer

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    Surging sales of Lundbeck's CNS drugs assist recovery. Two newer antidepressants help boost sales after Cipralex patent ends. ... Surging sales of four new central nervous system drugs helped Denmark's Lundbeck post a 5% sales increase in the second

  • Pfizer maintains lead in top CNS drug sales - just Pfizer maintains lead in top CNS drug sales - just

    It is also now Pfizer's top-selling medicine after the 2012 patent expiry of its once £13bn a year statin Lipitor (atorvastatin). ... The drug will now start to lose a massive $6.2bn by 2019 as the result of generic competition, making it the biggest

More from news
Approximately 3 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    The dream is that, on Day One when the product loses its patent, 100% of the patients use the biosimilar and the opportunity has been optimised. ... biosimilar and the promise of Mylan’s pipeline, which is fuelled by an annual Research &Development

  • Change in the pharma industry is inevitable Change in the pharma industry is inevitable

    The industry’s patent cliff is nothing new but the targeted, specialist nature of the latest generation of drugs is making it increasingly challenging to deliver a return on investment within ... the 10-year window that a patent is in force.

  • Building a bright future Building a bright future

    the patent cliff of high-value biologics across Europe. ... We are in the front of a big patent cliff which creates a tremendous opportunity.”.

  • Pharma deals during August 2014 Pharma deals during August 2014

    Will the fools or angels win out? The prospect of lost revenues resulting from Lantus' tumble off the patent cliff next year seems to be sufficient motivation for Sanofi, one of

  • Back to the future Back to the future

    And at the same time, the impact of generic erosion and the patent cliff continues to wipe billions of dollars off their shareholder value. ... The leaders in pharma showed high levels of resilience through 2013, despite the continuing fallout from the

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics